Evidence map›Paper›PMID 23449352›Full record

Trial reportBritish journal of cancer2013

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.

T Meyer, A Kirkwood, M Roughton, S Beare, E Tsochatzis, D Yu, N Davies, E Williams, S P Pereira, D Hochhauser and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04803019 (Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. A Randomized Controlled Trial), which is not on this map. Cited by 76 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 10 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04803019 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. A Randomized Controlled Trial

TypeinterventionalSponsorIRCCS Azienda Ospedaliero-Universitaria di BolognaRan2019 to 2022Enrolled154ConditionsCarcinoma, HepatocellularArmsDEB-TACE, TAE
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 10 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

T MeyerDepartment of Oncology, UCL Medical School, Royal Free Campus, London NW3 2QG, UK. t.meyer@ucl.ac.uk
A Kirkwood
M Roughton
S Beare
E Tsochatzis
D Yu
N Davies
E Williams
S P Pereira
D Hochhauser
A Mayer
R Gillmore
J O'Beirne
D Patch
A K Burroughs
Royal Free London NHS Foundation Trust · GBUniversity College London · GBCancer Research UK · GBCRUK Lung Cancer Centre of Excellence · GBRoland Hill (United Kingdom) · GBThe Royal Free Hospital · GBUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransarterial chemoembolisation (TACE) has not been shown to be superior to bland embolisation (TAE) for treatment of hepatocellular carcinoma (HCC).

methodsWe conducted a randomised phase II/III trial in patients with untreated HCC. Patients were randomised to TAE with polyvinyl alcohol (PVA) particles alone or sequential TACE (sTACE) in which cisplatin 50 mg was administered intrarterially 4-6 h before PVA embolisation. Treatment was repeated 3-weekly for up to three treatments. The primary endpoint was overall survival and secondary endpoints were progression-free survival, toxicity and response. Target sample sizes for phase II and III were 80 and 322.

resultsThe trial was terminated at phase II after 86 patients had been randomised. Patients were well matched for prognostic criteria. All three planned treatments were given to 57.1% (TAE) and 56.8% (TACE) patients. Grade 3/4 toxicity occurred in 63.5% and 83.7%, respectively (P=0.019). End-of-treatment RECIST response (CR+PR) was 13.2 and 32.6% (P=0.04) (mRECIST 47.3% and 67.4) and median overall survival and progression-free survival was 17.3 vs 16.3 (P=0.74) months and 7.2 vs 7.5 (P=0.59), respectively.

conclusionTransarterial chemoembolisation according this novel schedule is feasible and associated with a higher response rate than TAE alone. The survival benefit of TACE over TAE remains unproven.

Indexed as

Chemoembolization, TherapeuticEmbolization, TherapeuticAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularCisplatinCombined Modality TherapyFeasibility StudiesFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMiddle AgedAntineoplastic AgentsCisplatin

Identifiers

PMID23449352
PMCPMC3619271
OpenAlexW2032224733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.